News
Timely intervention: First chronic kidney disease treatment in 20 years
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending AstraZeneca’s Forxiga (dapagliflozin) within its marketing authorisation for the treatment of adults with chronic kidney disease (CKD).